DE2438350C3 - Peptide mit starker LH-RH/FSH-RH-Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen - Google Patents

Peptide mit starker LH-RH/FSH-RH-Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen

Info

Publication number
DE2438350C3
DE2438350C3 DE2438350A DE2438350A DE2438350C3 DE 2438350 C3 DE2438350 C3 DE 2438350C3 DE 2438350 A DE2438350 A DE 2438350A DE 2438350 A DE2438350 A DE 2438350A DE 2438350 C3 DE2438350 C3 DE 2438350C3
Authority
DE
Germany
Prior art keywords
pro
arg
ser
leu
residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE2438350A
Other languages
German (de)
English (en)
Other versions
DE2438350A1 (de
DE2438350B2 (de
Inventor
Rolf Dr. Geiger
Wolfgang Dr. 6239 Langenhain Koenig
Juergen Dr. Sandow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Priority to DE2438350A priority Critical patent/DE2438350C3/de
Priority to NLAANVRAGE7509260,A priority patent/NL182051C/xx
Priority to IL47880A priority patent/IL47880A/xx
Priority to CH1028175A priority patent/CH613186A5/xx
Priority to US05/602,910 priority patent/US4024248A/en
Priority to AU83744/75A priority patent/AU495372B2/en
Priority to CA233,179A priority patent/CA1069888A/en
Priority to LU73166A priority patent/LU73166A1/xx
Priority to SE7508926A priority patent/SE424184B/xx
Priority to IE1771/75A priority patent/IE41510B1/en
Priority to DK361875A priority patent/DK148905C/da
Priority to AT0618975A priority patent/AT364093B/de
Priority to JP50096316A priority patent/JPS5761268B2/ja
Priority to BE159095A priority patent/BE832310A/xx
Priority to FR7524951A priority patent/FR2281132A1/fr
Publication of DE2438350A1 publication Critical patent/DE2438350A1/de
Priority to GB33426/75A priority patent/GB1523623A/en
Priority to SE7805545A priority patent/SE7805545L/sv
Publication of DE2438350B2 publication Critical patent/DE2438350B2/de
Application granted granted Critical
Publication of DE2438350C3 publication Critical patent/DE2438350C3/de
Priority to AT249180A priority patent/AT373232B/de
Priority to AT249280A priority patent/AT372941B/de
Priority to DK439683A priority patent/DK148906C/da
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/13—Luteinizing hormone-releasing hormone; related peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE2438350A 1974-08-09 1974-08-09 Peptide mit starker LH-RH/FSH-RH-Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen Expired DE2438350C3 (de)

Priority Applications (20)

Application Number Priority Date Filing Date Title
DE2438350A DE2438350C3 (de) 1974-08-09 1974-08-09 Peptide mit starker LH-RH/FSH-RH-Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
NLAANVRAGE7509260,A NL182051C (nl) 1974-08-09 1975-08-04 Werkwijze voor de bereiding van een farmaceutisch preparaat met lh/fsh-afgifte teweegbrengende werking, voor de bereiding van peptiden, geschikt voor toepassing in deze preparaten, alsmede gevormd farmaceutisch preparaat.
IL47880A IL47880A (en) 1974-08-09 1975-08-05 Peptides having strong lh-rh/fsh-rh lh-rh/fsh-rh activity and process for their manufacture
CH1028175A CH613186A5 (enExample) 1974-08-09 1975-08-06
AU83744/75A AU495372B2 (en) 1975-08-07 Peptides having strong lh-rh/fsh-rh activity and process for their manufacture
CA233,179A CA1069888A (en) 1974-08-09 1975-08-07 Peptides having strong lh-rh/fsh-rh activity and process for their manufacture
LU73166A LU73166A1 (enExample) 1974-08-09 1975-08-07
SE7508926A SE424184B (sv) 1974-08-09 1975-08-07 Forfarande for framstellning av peptider med kraftig lh-rh/fsh-rh-verkan
US05/602,910 US4024248A (en) 1974-08-09 1975-08-07 Peptides having LH-RH/FSH-RH activity
DK361875A DK148905C (da) 1974-08-09 1975-08-08 Analogifremgangsmaade til fremstilling af lh-rh-analoge nonapeptidderivater
IE1771/75A IE41510B1 (en) 1974-08-09 1975-08-08 Peptides having lh-rh/fsh-rh activity and proces for their manufacture
AT0618975A AT364093B (de) 1974-08-09 1975-08-08 Verfahren zur herstellung von neuen peptiden
JP50096316A JPS5761268B2 (enExample) 1974-08-09 1975-08-09
BE159095A BE832310A (fr) 1974-08-09 1975-08-11 Peptides ayant une forte activite d'hormone liberant l'hormone luteinisante ou d'hormone liberant l'hormone folliculostimulante (hl - hl/hl - hfs) et leur procede de preparation, et leur application
FR7524951A FR2281132A1 (fr) 1974-08-09 1975-08-11 Peptides ayant une forte activite d'hormone liberant l'hormone luteinisante ou d'hormone liberant l'hormone folliculostimulante (hl-hl/hl-hfs) et leur procede de preparation et leur application
GB33426/75A GB1523623A (en) 1974-08-09 1976-08-11 Activity and process for their manufacture
SE7805545A SE7805545L (enExample) 1974-08-09 1978-05-16
AT249180A AT373232B (de) 1974-08-09 1980-05-09 Verfahren zur herstellung von neuen peptiden
AT249280A AT372941B (de) 1974-08-09 1980-05-09 Verfahren zur herstellung von neuen peptiden
DK439683A DK148906C (da) 1974-08-09 1983-09-26 Lh-rh-analoge nonapeptidderivater til diagnostisk anvendelse

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2438350A DE2438350C3 (de) 1974-08-09 1974-08-09 Peptide mit starker LH-RH/FSH-RH-Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen

Publications (3)

Publication Number Publication Date
DE2438350A1 DE2438350A1 (de) 1976-02-26
DE2438350B2 DE2438350B2 (de) 1978-10-26
DE2438350C3 true DE2438350C3 (de) 1979-06-13

Family

ID=5922833

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2438350A Expired DE2438350C3 (de) 1974-08-09 1974-08-09 Peptide mit starker LH-RH/FSH-RH-Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen

Country Status (15)

Country Link
US (1) US4024248A (enExample)
JP (1) JPS5761268B2 (enExample)
AT (1) AT364093B (enExample)
BE (1) BE832310A (enExample)
CA (1) CA1069888A (enExample)
CH (1) CH613186A5 (enExample)
DE (1) DE2438350C3 (enExample)
DK (1) DK148905C (enExample)
FR (1) FR2281132A1 (enExample)
GB (1) GB1523623A (enExample)
IE (1) IE41510B1 (enExample)
IL (1) IL47880A (enExample)
LU (1) LU73166A1 (enExample)
NL (1) NL182051C (enExample)
SE (2) SE424184B (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2617646C2 (de) * 1976-04-22 1986-07-31 Hoechst Ag, 6230 Frankfurt Nonapeptid-amide und Decapeptid-amide mit Gonadoliberin-Wirkung, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
GB1524747A (en) * 1976-05-11 1978-09-13 Ici Ltd Polypeptide
DE2735515A1 (de) * 1977-08-06 1979-02-22 Hoechst Ag Verwendung von lh-rh-peptiden als antikonzeptive
FR2450109B1 (fr) * 1977-11-08 1986-03-28 Roussel Uclaf Nouvelle methode de traitement utilisant la lh-rh, ou des agonistes
IT1149971B (it) * 1979-06-11 1986-12-10 Syntex Inc Derivati nonapeptide e decapeptide dell'ormone che rilascia l'ormone luteinizzante
US4234571A (en) * 1979-06-11 1980-11-18 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
DE3020941A1 (de) * 1980-06-03 1981-12-17 Hoechst Ag, 6000 Frankfurt Nonapeptid, verfahren zu seiner herstellung, dieses enthaltendes mittel und seine verwendung
HU185535B (en) * 1982-05-25 1985-02-28 Mta Koezponti Hivatala Process for preparing new gonadoliberin derivatives
HU187503B (en) * 1983-03-29 1986-01-28 Magyar Tudomanyos Akademia,Hu Process for preparing gonadoliberine derivatives containing beta-aspartyl group
AT390066B (de) * 1983-03-29 1990-03-12 Richter Gedeon Vegyeszet Verfahren zur herstellung von neuen gonadoliberin-derivaten
DE3411224A1 (de) * 1984-03-27 1985-10-10 Hoechst Ag, 6230 Frankfurt Verfahren zur racematarmen herstellung von peptidzwischenprodukten der gonadorelin- und gonadorelinanaloga-synthese und neue zwischenprodukte bei diesem verfahren
US4775660A (en) * 1984-08-02 1988-10-04 Fernand Labrie Treatment of breast cancer by combination therapy
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
HU193093B (en) * 1985-04-16 1987-08-28 Innofinance Process for stimulating sexual activity of birds and domestic mammalians and process for producing spermatocytes for their propagation
HU194280B (en) * 1985-10-22 1988-01-28 Richter Gedeon Vegyeszet Process for producing new gonadoliberin analogues of high effectivity and pharmaceutical compositions containing them
PH30747A (en) * 1989-03-10 1997-10-17 Endorech Inc Combination therapy for the treatment of estrogen sensitive disease.
US5372996A (en) * 1989-03-10 1994-12-13 Endorecherche, Inc. Method of treatment of androgen-related diseases
JPH0235232A (ja) * 1989-06-29 1990-02-05 Nhk Spring Co Ltd 気室と液室を有する圧力容器
DK0595796T3 (da) * 1989-07-07 2003-05-05 Endorech Inc Fremgangsmåde til behandling af androgen-relaterede sygdomme
JP2959839B2 (ja) * 1989-07-07 1999-10-06 アンドルシェルシュ・インコーポレイテッド 性ステロイド活性の抑制における使用のためのアンドロゲン誘導体
CA2029018A1 (en) * 1989-11-01 1991-05-02 Robert P. Millar Analogues of gonadotropin releasing hormone
JPH0474770U (enExample) * 1990-10-31 1992-06-30
KR950701527A (ko) * 1992-05-21 1995-04-28 라브리 페르낭 테스토스테론 5α 환원효소 활성 저해제(INHIBITORS OF TESTOSTERONE 5α-REDUCTASE ACTIVITY)
US7833543B2 (en) * 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
CA2192773C (en) 1995-12-15 2008-09-23 Hiroaki Okada Production of sustained-release preparation for injection
US20060025328A1 (en) * 1997-05-28 2006-02-02 Burns Patrick J Compositions suitable for controlled release of the hormone GnRH and its analogs
US6051558A (en) * 1997-05-28 2000-04-18 Southern Biosystems, Inc. Compositions suitable for controlled release of the hormone GnRH and its analogs
US6242421B1 (en) 1997-11-06 2001-06-05 Richard Lloyd Bowen Methods for preventing and treating Alzheimer's disease
ES2154590B1 (es) 1999-05-20 2001-11-01 Lipotec Sa Procedimiento de sintesis de peptidos en fase solida
AR023940A1 (es) 2000-05-03 2002-09-04 Eriochem Sa Procedimiento para la produccion de microcapsulas de liberacion prolongada de peptidos solubles en agua
CA2451187C (en) * 2001-06-22 2012-08-14 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
US20060287282A1 (en) * 2001-06-25 2006-12-21 Steiner Mitchell S Compositions comprising a SARM ad GnRH agonist or a GnRH antagonist, and methods of use thereof
WO2003015820A1 (en) * 2001-08-10 2003-02-27 Takeda Chemical Industries, Ltd. GnRH AGONIST COMBINATION DRUGS
EP1444988A4 (en) 2001-11-13 2007-04-25 Takeda Pharmaceutical CANCER AGENT
US20030144203A1 (en) * 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
EP2218448B1 (en) 2002-12-13 2015-09-23 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
GB0307777D0 (en) * 2003-04-04 2003-05-07 Medical Res Council Conjugate compounds
DK2767292T3 (en) 2004-09-17 2016-12-19 Durect Corp RENEWABLE local anesthetic COMPOSITION CONTAINING SAIB
EP1845973B1 (en) 2005-01-21 2015-08-12 Astex Therapeutics Limited Pharmaceutical compounds
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US20070106271A1 (en) * 2005-11-09 2007-05-10 Searete Llc, A Limited Liability Corporation Remote control of substance delivery system
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
AU2007325918B2 (en) 2006-11-03 2013-10-17 Durect Corporation Transdermal delivery systems comprising bupivacaine
EP2067471B1 (en) * 2007-12-06 2018-02-14 Durect Corporation Oral pharmaceutical dosage forms
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
RU2444525C2 (ru) * 2010-06-09 2012-03-10 Закрытое Акционерное Общество "Фарм-Синтез" Способ получения нонапептидэтиламида и промежуточные соединения для его получения
SG186333A1 (en) 2010-06-16 2013-01-30 Endorech Inc Methods of treating or preventing estrogen-related diseases
CA2905131A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
CN109475505A (zh) 2016-07-06 2019-03-15 度瑞公司 具有药物组成物、屏障层及药物层的口服剂型
WO2021146215A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
CA3203561A1 (en) 2021-01-12 2022-07-21 Adrian Neil Verity Sustained release drug delivery systems and related methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5726506B2 (enExample) * 1974-03-08 1982-06-04
US3914412A (en) * 1973-10-11 1975-10-21 Abbott Lab {8 Des{13 Gly{9 {0 10 -Gn{13 RH nonapeptide amide analogs in position 6 having ovulation-inducing activity
US3901872A (en) * 1974-03-13 1975-08-26 American Home Prod P-glu-his-trp-ser-tyr-d-pgl-leu-arg-pro-gly-nh' 2 'and intermediates
US3896104A (en) * 1974-05-22 1975-07-22 American Home Prod P-glu-his-trp-ser-tyr-d-lys-leu-arg-pro-gly-nh' 2 'and intermediates

Also Published As

Publication number Publication date
FR2281132B1 (enExample) 1979-09-14
FR2281132A1 (fr) 1976-03-05
JPS5148659A (enExample) 1976-04-26
JPS5761268B2 (enExample) 1982-12-23
NL7509260A (nl) 1976-02-11
NL182051B (nl) 1987-08-03
AT364093B (de) 1981-09-25
CA1069888A (en) 1980-01-15
IE41510L (en) 1976-02-09
DK148905B (da) 1985-11-11
GB1523623A (en) 1978-09-06
IL47880A0 (en) 1975-11-25
LU73166A1 (enExample) 1977-04-13
CH613186A5 (enExample) 1979-09-14
IL47880A (en) 1978-10-31
BE832310A (fr) 1976-02-11
NL182051C (nl) 1988-01-04
ATA618975A (de) 1981-02-15
DK361875A (da) 1976-02-10
US4024248A (en) 1977-05-17
DE2438350A1 (de) 1976-02-26
DE2438350B2 (de) 1978-10-26
SE7805545L (enExample) 1978-05-16
DK148905C (da) 1986-04-07
SE424184B (sv) 1982-07-05
IE41510B1 (en) 1980-01-16
AU8374475A (en) 1977-02-10
SE7508926L (sv) 1976-02-10

Similar Documents

Publication Publication Date Title
DE2438350B2 (de) Peptide mit starker LH-RH/FSH-RH-Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
DE2617646C2 (de) Nonapeptid-amide und Decapeptid-amide mit Gonadoliberin-Wirkung, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
JP2919965B2 (ja) デヒドロジデムニンｂ
EP0001295B1 (de) Somatostatin-analoge Cyclopeptide, Verfahren zu ihrer Herstellung, pharmazeutische Präparate enthaltend diese Verbindungen, sowie ihre therapeutische Anwendung
US4490291A (en) Nonapeptide amides
CH629475A5 (de) Verfahren zur herstellung von polypeptiden.
DE3587016T2 (de) Nona- und dekapeptidanaloga von lhrh, welche als lhrh-antagonisten dienen.
EP0023192A1 (de) Cyclopeptide und pharmazeutische Präparate davon, sowie Verfahren zu ihrer Herstellung und deren Anwendung
CH634039A5 (de) Somatostatinanalogon, sowie verfahren zu seiner herstellung.
JPH03501969A (ja) 極く僅かのヒスタミンを放出するホルモン放出黄体形成ホルモンの効果的拮抗物質
DE2438352A1 (de) Peptidcyclopropylamide mit lh-rh/fshrh-wirkung
EP0106404B1 (en) Peptides
WO1996005189A1 (de) Neue inhibitoren vom benzamidintyp
HUT64776A (en) Methods for producing cyclopeptides promoting absorption of peptides and albumins through mucous membrane as well as pharmaceutical preparations containing said compounds as auxiliary agents
US4075191A (en) Biologically active amides
DE2726276A1 (de) Polypeptid
DE2718718A1 (de) Somatostatinanaloge und zwischenprodukte hierzu
DE2830489A1 (de) Psychopharmakologisch wirksame peptide
EP0041243B1 (de) Nonapeptid, Verfahren zu seiner Herstellung, dieses enthaltendes Mittel und seine Verwendung
DE2532823A1 (de) Neue polypeptide
DE69626507T2 (de) Lhrh-antagonisten
DD217808A5 (de) Verfahren zur herstellung von saeugetier-pgrf
AT373232B (de) Verfahren zur herstellung von neuen peptiden
US4358440A (en) Polypeptide and its production and use
DD296084A5 (de) Verfahren zur herstellung von humanen spleninderivaten

Legal Events

Date Code Title Description
C3 Grant after two publication steps (3rd publication)